Latest Articles
- ArticlePharmacogenomic study in patients with multiple sclerosisResponders and nonresponders to IFN-βMarta F. Bustamante, Carlos Morcillo-Suárez, Sunny Malhotra, et al.September 24, 2015
- EditorialSubtype-specific therapy for autoimmune neuropathies?Eric Lancaster, Steven S. SchererSeptember 24, 2015
- ArticleGray matter–related proteins are associated with childhood-onset multiple sclerosisVaibhav Singh, E. Daniëlle van Pelt, Marcel P. Stoop, et al.September 24, 2015
- ArticleGRIN1 polymorphisms do not affect susceptibility or phenotype in NMDA receptor encephalitisGregory S. Day, Harald Prüss, Susanne M. Benseler, et al.September 24, 2015
- ArticleEffects of diazoxide in multiple sclerosisA randomized, double-blind phase 2 clinical trialPablo Villoslada, Alex Rovira, Xavier Montalban, et al.September 10, 2015
- ArticleRituximab in treatment-resistant CIDP with antibodies against paranodal proteinsLuis Querol, Ricard Rojas-García, Jordi Diaz-Manera, et al.September 03, 2015
- ArticleDirect MRI detection of impending plaque development in multiple sclerosisMartina Absinta, Govind Nair, Pascal Sati, et al.September 03, 2015
- ArticleImmunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MSMaria Zimmermann, Nicholas S.R. Sanderson, Maria Rasenack, et al.August 20, 2015
- ArticleDeregulated Fcγ receptor expression in patients with CIDPIsaak Quast, Flavio Cueni, Falk Nimmerjahn, et al.August 20, 2015
- Clinical/Scientific NotesFaciobrachio-crural dystonic seizures in LGI1 limbic encephalitis: A treatable cause of fallsFatme Seval Ismail, Stoyan Popkirov, Jörg Wellmer, et al.August 20, 2015
Pages
Advertisement